New opioid painkiller may rival OxyContin in the marketplace

As the pharmaceutical companies Grunenthal and Johnson & Johnson release positive final-stage trial results for their new opioid painkiller tapentadol extended-release, market predictors estimate the new drug will rival or possibly even replace OxyContin as the top medication for chronic pain. According to this article in Trading Markets.com, Datamonitor forecasts sales to reach over $800 million by 2019. If approved for sale in the U.S., tapentadol will be the first new opioid to reach the marketplace in over 25 years. As an opioid-based, Schedule II drug like OxyContin, tapentadol may also become highly addictive and should be used under careful supervision, states Johnson & Johnson in this press release.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Pharmaceutical Industry and tagged , , , , , , , , , . Bookmark the permalink.

One Response to New opioid painkiller may rival OxyContin in the marketplace

  1. Pingback: Tweets that mention New opioid painkiller may rival OxyContin in the marketplace « Oxy Watchdog -- Topsy.com

Leave a Reply

Your email address will not be published. Required fields are marked *